COMMUNIQUÉS West-GlobeNewswire

Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month
14/05/2025
New national awareness day will foster greater understanding of transcranial magnetic stimulation (TMS) treatment The company will celebrate on social media, sharing patient and provider stories that highlight the [...]
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
14/05/2025
Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar Market SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a [...]
Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results
14/05/2025
- VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial - - Closed a public offering on May 8, 2025, raising the Company’s cash balance and [...]
Cannabix Enters Sales Distribution Agreement with Australian Distributor for BreathLogix Autonomous Alcohol Breathalyzer
14/05/2025
Cannabix has developed an autonomous alcohol breathalyzer screening device for employers and a range of industries and safety settings VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies [...]
Epilepsy Foundation of America to Present Lifetime Accelerator Award to Orrin Devinsky, M.D.
14/05/2025
Renowned Neurologist and Epilepsy Advocate Honored for Decades of Innovation in Therapeutics, Research, and Patient Care BOWIE, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Internationally acclaimed neurologist and epilepsy [...]
The Dwayne Andrews Glioblastoma Research Grant Awarded to Dr. Jeremy Brown, Dalhousie University
14/05/2025
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is proud to announce The Dwayne Andrews Glioblastoma Research Grant of $85,000 awarded to Dr. Jeremy Brown at Dalhousie University for his project, "Clinical [...]
Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
14/05/2025
– Expect to report topline data from the Seabreeze STAT COPD study in 1H 2026 – SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), [...]
Outset Medical Appoints Industry Veteran Kevin O’Boyle to its Board of Directors
14/05/2025
SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, [...]
Progyny Appoints Two Renowned Women’s Health Experts to Medical Advisory Board
14/05/2025
Medical Advisory Board additions support company’s growing product offerings across women’s health and family building NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s [...]
Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call
14/05/2025
Call Scheduled for Thursday, May 15, 2025 at 5:00 pm ET LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS) , a leading medical device and technology [...]
Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform
14/05/2025
New Proprietary Target Discovery and Validation Platform Integrates Multiomics, Contingent AI, Phenoclustering, and CRISPR Screens to Accelerate Drug Discovery LOS ANGELES, May 14, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc [...]
Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event
14/05/2025
Live webcast followed by an interactive Q&A session on Thursday, May 22 nd at 4:00 PM ET Access the event here THE WOODLANDS, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” [...]
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
14/05/2025
Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations Early dose-escalation data from Phase 1 CARDINAL study [...]
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)
14/05/2025
– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts highlight the [...]
Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference
14/05/2025
Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular [...]
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress
14/05/2025
Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia [...]
Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma
14/05/2025
SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein [...]
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
14/05/2025
Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy Data [...]
Angelini Ventures Invests into $39 Million Series A Extension Round for Therini Bio, a Clinical Stage Company Developing Fibrin-targeting Immunotherapies for Neurodegenerative Diseases
14/05/2025
Angelini Ventures joins top-tier investor syndicate Investment will fund Phase 1b studies evaluating Therini Bio’s lead candidate, THN391, for the treatment of Alzheimer’s Disease (AD) and Diabetic Macular Edema (DME), [...]

Pages